Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025

Reuters

11/15

Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025

Verrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576282-en) on November 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583681748"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583681748\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583681748?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583681748","market":"nz","top_or_hot":-1,"title":"Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576282-en) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-15 05:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576282-en) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLbTGl1x:1","article_id":"2583681748","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583681748","pubTimestamp":1763154325,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","VRCA":"Verrica Pharmaceuticals Inc.","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Verrica Pharmaceuticals报告2025年第三季度收入为1,430万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"VRCA":0.9},"content_text":"Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025\n    \n\nVerrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576282-en) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}